Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Tenofovir disoproxil fumarate→

Tenofovir disoproxil fumarate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
202138-50-9
PubChem CID
6398764
Molecular formula
C23H34N5O14P
Molecular weight
635.5 g/mol
Drug class
Acyclic nucleotide phosphonate prodrugantiretroviral reverse-transcriptase inhibitor precursor
Mechanism of action
Tenofovir disoproxil is a prodrug that is hydrolysed to tenofovir and subsequently phosphorylated intracellularly to tenofovir diphosphate. Tenofovir diphosphate competitively inhibits HIV reverse transcriptase and HBV DNA polymerase and causes DNA-chain termination. Fumarate is the salt component; the disoproxil moiety is the prodrug.
Indications / reported uses
  • Treatment of HIV-1 infection in combination with other antiretroviral agents
  • Treatment of chronic hepatitis B in adults and adolescents where authorised; use requires current product-specific eligibility, renal assessment and monitoring

Sources: US DailyMed — Tenofovir disoproxil fumarate · EMA — Viread · NIH HIV drug information — Tenofovir disoproxil fumarate

Identification source: PubChem record (CID 6398764). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Tenofovir disoproxil fumarate Environmental Risk Assessment (ERA) (the Tenofovir disoproxil fumarate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.